CDH15

Across TCGA pan-cancer cohorts, CDH15 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDH15 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher CDH15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDH15 expression acts as an unfavorable survival marker.

PAAD, UCEC, and MESO are the cancer types where CDH15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.037	0.641	<.001	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
HNSC	DFS	Median	All	0.347	0.604	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDH15–PAAD (OS)

Open the PAAD breakdown →